Omega-3 Inflammation Randomized Trial: What the Evidence Says

Quick Answer

Omega-3 Inflammation Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 2 randomized trial.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Metabolic syndrome (MetS), one of the most prevalent chronic disorders worldwide, is a clinical entity characterized by central obesity, hypertension, dysglycemia, elevated triglycerides, and reduced high-density lipoprotein cholesterol. [Yang Haiyue (2026); evidence level 2]
• The prevalence of metabolic syndrome (MetS) remains high among community-dwelling older adults aged 65 years and older, and is associated with elevated risks of cardiovascular disease, type 2 diabetes mellitus, and physical functional decline. [Yang Haiyue (2026); evidence level 2]
• Chronic kidney disease (CKD) is characterized by persistent abnormalities in the structure, function, or both of the kidneys, and is associated with patients developing systemic complications. [Shafaei Kachaei Hanieh (2026); evidence level 2]
• Post hoc power analysis for CRP and IL-6 outcomes revealed that the study had a power of approximately 62% to detect a moderate effect size (Cohen's d≈0.5), indicating a potential risk of Type II error due to sample size limitations. [Shafaei Kachaei Hanieh (2026); evidence level 2]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For omega-3 inflammation randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Yang Haiyue (2026). Effects of omega-3 PUFA-enriched egg consumption on metabolic parameters in elderly adults with metabolic syndrome: study protocol for a randomized controlled trial. DOI: 10.3389/fnut.2026.1831128. PMCID: PMC13226538. PMID: 42239715. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13226538/
• Shafaei Kachaei Hanieh (2026). Modulation of Inflammatory Indices by Omega‐3 Fatty Acids Supplementation in Hemodialysis: A Clinical Trial Approach. DOI: 10.1111/cts.70531. PMCID: PMC13121090. PMID: 42045798. License: https://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/ This is an open access.... https://pmc.ncbi.nlm.nih.gov/articles/PMC13121090/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.